Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Endocrinology 2, 7–8 (1 January 2006) | doi:10.1038/ncpendmet0065
PTHrP modifies the efficacy of administered PTH 1|[ndash]|34: implications for osteoporosis treatment
Abstract
Miao D et al. (2005) Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34. J Clin Invest 115: 2402–2411 Most therapies for osteoporosis slow the resorption of bone.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
